Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 70/100

Failure Rate

27.3%

3 terminated/withdrawn out of 11 trials

Success Rate

66.7%

-19.8% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

133%

8 of 6 completed trials have results

Key Signals

8 with results

Enrollment Performance

Analytics

Phase 2
6(66.7%)
Phase 1
3(33.3%)
9Total
Phase 2(6)
Phase 1(3)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (11)

Showing 11 of 11 trials
NCT03756311Unknown

Expanded Access to NanoPac

Role: lead

NCT04060628Unknown

Expanded Access to NanoDoce

Role: lead

NCT04314895Phase 2Completed

Trial of NanoPac Intratumoral Injection in Lung Cancer

Role: lead

NCT03077685Phase 2Completed

Trial of NanoPac® in Subjects With Locally Advanced Pancreatic Adenocarcinoma

Role: lead

NCT03636256Phase 1Completed

Evaluation of NanoDoce® in Participants With Urothelial Carcinoma

Role: lead

NCT04221828Phase 2Terminated

Trial of NanoPac Focal Therapy for Prostate Cancer

Role: lead

NCT03101358Phase 1Completed

Study of Topical SOR007 Ointment for Cutaneous Metastases

Role: lead

NCT03188991Phase 2Completed

Intracystic Injection of NanoPac® in Subjects With Mucinous Cystic Pancreatic Neoplasms

Role: lead

NCT03029585Phase 2Terminated

Phase II Study of Intraperitoneal NanoPac® in Patients With Ovarian Cancer

Role: lead

NCT04260360Phase 1Withdrawn

Trial of NanoDoce Intratumoral Injection in Renal Cell Carcinoma

Role: lead

NCT03077659Phase 2Completed

Trial of NanoPac® Focal Therapy in Subjects With Prostate Cancer

Role: lead

All 11 trials loaded